Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 1
2004 1
2005 3
2006 1
2008 2
2009 2
2010 1
2011 2
2012 5
2013 6
2014 4
2015 2
2016 4
2017 2
2018 5
2019 12
2020 7
2021 8
2022 10
2023 10
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

81 results

Results by year

Filters applied: . Clear all
Page 1
Proteomics profiling of colorectal cancer progression identifies PLOD2 as a potential therapeutic target.
Shao Y, Xu K, Zheng X, Zhou B, Zhang X, Wang L, Sun Y, Li D, Chen T, Wang J, Yu S, Sun L, Xu X, Dai S, Gao H, Ruan G, Liu W, Cai X, Zhu T, Qi L, Chen J, Hu W, Weng X, Zhu Y, Xiang X, Hu Z, Li J, Chen L, Shao J, Zheng S, Guo T. Shao Y, et al. Among authors: sun l. Cancer Commun (Lond). 2022 Feb;42(2):164-169. doi: 10.1002/cac2.12240. Epub 2021 Dec 4. Cancer Commun (Lond). 2022. PMID: 34862750 Free PMC article. No abstract available.
Sintilimab plus bevacizumab, oxaliplatin and capecitabine as first-line therapy in RAS-mutant, microsatellite stable, unresectable metastatic colorectal cancer: an open-label, single-arm, phase II trial.
Fang X, Zhu N, Zhong C, Wang L, Li J, Weng S, Hu H, Dong C, Li D, Song Y, Xu D, Wang J, Sun L, Wang J, Wang Z, Cao H, Liao X, Yu N, Xiao Q, Mi M, Zhang S, Ding K, Yuan Y. Fang X, et al. Among authors: sun l. EClinicalMedicine. 2023 Jul 27;62:102123. doi: 10.1016/j.eclinm.2023.102123. eCollection 2023 Aug. EClinicalMedicine. 2023. PMID: 37554125 Free PMC article.
A Randomized Phase III Study of Anlotinib Versus Bevacizumab in Combination With CAPEOX as First-Line Therapy for RAS/BRAF Wild-Type Metastatic Colorectal Cancer: A Clinical Trial Protocol.
He J, Liu Y, Liu C, Hu H, Sun L, Xu D, Li J, Wang J, Chen X, Lin R, Jiang Y, Zhang Y, Zhang W, Cheng Y, Wu X, Fang M, Li E, Xu Y, Chen Y, Li J, Cui Y, Pan Z, Zhang S, Yuan Y, Ding K. He J, et al. Among authors: sun l. Technol Cancer Res Treat. 2023 Jan-Dec;22:15330338231152350. doi: 10.1177/15330338231152350. Technol Cancer Res Treat. 2023. PMID: 36727222 Free PMC article.
Sintilimab plus bevacizumab and CapeOx (BBCAPX) on first-line treatment in patients with RAS mutant, microsatellite stable, metastatic colorectal cancer: study protocol of a randomized, open-label, multicentric study.
Fang X, Zhong C, Weng S, Hu H, Wang J, Xiao Q, Wang J, Sun L, Xu D, Liao X, Dong C, Zhang S, Li J, Ding K, Yuan Y. Fang X, et al. Among authors: sun l. BMC Cancer. 2023 Jul 18;23(1):676. doi: 10.1186/s12885-023-11139-z. BMC Cancer. 2023. PMID: 37464378 Free PMC article.
81 results